On June 21, Gelunhui reported that Fujilai (301258.SZ) announced on the investor interaction platform that its biocatalytic production of R-thioctic acid has been put into mass production. It is mainly used for external sales and preparation of R-thioctic acid sodium salt. Currently, it is still in the market promotion stage, and whether it can completely replace the original process depends on market demand, customer acceptance, and other factors. In 2023, the revenue from this type of business will account for no more than 3% of the company's total revenue, with a relatively small proportion, and there are no clear expansion plans yet.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
富士莱(301258.SZ):公司生物酶催化法生产的R-硫辛酸已经实现量产
Fujilai (301258.SZ): The company has achieved mass production of R-Octanoic acid produced by biocatalytic method.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 203
Write a comment
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report